Semin Musculoskelet Radiol 2024; 28(01): 049-061
DOI: 10.1055/s-0043-1776428
Review Article

Radiomics in Musculoskeletal Tumors

1   Department of Medical Imaging, Musculoskeletal Imaging, University of Toronto, Toronto, Ontario, Canada
2   Institut für Radiologie und Nuklearmedizin, Kantonsspital Baselland, Liestal, Switzerland
3   Toronto Joint Department of Medical Imaging, University Health Network, Sinai Health System, and Women's College Hospital, Mount Sinai Hospital, Toronto, Ontario, Canada
,
1   Department of Medical Imaging, Musculoskeletal Imaging, University of Toronto, Toronto, Ontario, Canada
3   Toronto Joint Department of Medical Imaging, University Health Network, Sinai Health System, and Women's College Hospital, Mount Sinai Hospital, Toronto, Ontario, Canada
› Author Affiliations
Preview

Abstract

Sarcomas are heterogeneous rare tumors predominantly affecting the musculoskeletal (MSK) system. Due to significant variations in their natural history and variable response to conventional treatments, the discovery of novel diagnostic and prognostic biomarkers to guide therapeutic decision-making is an active and ongoing field of research. As new cellular, molecular, and metabolic biomarkers continue to be discovered, quantitative radiologic imaging is becoming increasingly important in sarcoma management. Radiomics offers the potential for discovering novel imaging diagnostic and predictive biomarkers using standard-of-care medical imaging. In this review, we detail the core concepts of radiomics and the application of radiomics to date in MSK sarcoma research. Also described are specific challenges related to radiomic studies, as well as viewpoints on clinical adoption and future perspectives in the field.



Publication History

Article published online:
08 February 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA